MARKET

MYO

MYO

Myomo
AMEX

Real-time Quotes | Nasdaq Last Sale

7.44
-0.09
-1.20%
After Hours: 7.44 0 0.00% 16:00 12/03 EST
OPEN
7.64
PREV CLOSE
7.53
HIGH
7.64
LOW
7.09
VOLUME
120.10K
TURNOVER
--
52 WEEK HIGH
40.00
52 WEEK LOW
2.820
MARKET CAP
33.86M
P/E (TTM)
-0.8074
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AnPac Bio-Medical, Cocrystal Pharma leads healthcare gainers; Hepion Pharmaceuticals, Medigus among major losers
Gainers: AnPac Bio-Medical Science (ANPC) +110%, Cocrystal Pharma (COCP) +56%, Renalytix AI (RNLX) +31%, Precigen (PGEN) +13%, Chiasma (CHMA) +11%.Losers: Hepion Pharmaceuticals (HEPA) -29%, Medigus (MDGS) -12%, Retractable Technologies (RVP) -10%, Mesoblast (MESO) -9%, Myomo (MYO) -9%.
Seekingalpha · 11/25 15:55
Myomo to Present at Sidoti & Company Virtual Microcap Conference
Business Wire · 11/18 14:03
Myomo to Present at Sidoti & Company Virtual Microcap Conference
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be presenting at the Sidoti & Company Virtual Microcap Conference on Thursday, November 19, 2020 at 1:45 p.m. Eastern Time.
BusinessWire · 11/18 11:03
Myomo Introduces MyoGames
Myomo Introduces MyoGames™ Video Games Played via MyoPro for Training, Rehabilitation and Fun Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company
Benzinga · 11/16 13:32
Myomo Introduces MyoGames™
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun. MyoGames enables users to play video games by actively engaging their paralyzed or weakened arm or hand with the MyoPro. The first game, basketball, is available immediately with other titles to follow.
Business Wire · 11/16 13:30
Myomo Introduces MyoGames(TM)
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun. MyoGames enables users to play video games by actively engaging their paralyzed or weakened arm or hand with the MyoPro. The first game, basketball, is available immediately with other titles to follow.
BusinessWire · 11/16 10:30
How Much Does Myomo's (NYSEMKT:MYO) CEO Make?
Paul Gudonis has been the CEO of Myomo, Inc. (NYSEMKT:MYO) since 2011, and this article will examine the executive's...
Simply Wall St. · 11/12 12:28
ROCE Insights For Myomo
During Q3, Myomo (AMEX: MYO) brought in sales totaling $1.93 million. However, earnings decreased 10.65%, resulting in a loss of $2.55 million. Myomo collected $858.59 thousand in revenue during Q2, but reported earnings showed a $2.85 million loss.Why ROCE Is Significant Changes in earnings and sales indicate shifts in Myomo's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Myomo posted an ROCE of -0.2%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on MYOROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Myomo is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Myomo's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Insight Myomo reported Q3 earnings per share at $-0.65/share, which beat analyst predictions of $-1.05/share.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/11 15:01
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYO. Analyze the recent business situations of Myomo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYO stock price target is 10.25 with a high estimate of 14.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 1.72M
% Owned: 37.64%
Shares Outstanding: 4.58M
TypeInstitutionsShares
Increased
5
181.43K
New
2
182.53K
Decreased
3
53.28K
Sold Out
7
253.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.85%
Healthcare Equipment & Supplies
-1.15%
Key Executives
Chairman/President/Founder/Chief Operating Officer/Director
Steve Kelly
Chief Executive Officer/Director
Paul Gudonis
Chief Financial Officer/Chief Accounting Officer
David Henry
General Manager
Jonathan Naft
Other
Fredrick Nahm
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MYO
Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Myomo Inc stock information, including AMEX:MYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYO stock methods without spending real money on the virtual paper trading platform.